Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025
Company announcement
No. 08/2025
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
KONGENS LYNGBY, Denmark ,
"In 2025, we expect to be back on our previous growth track as we advance on our journey towards profitability. The commercial traction is resuming, and we have a growing inflow of orders that will materialize throughout the year," says
"As in previous years, we expect revenue to be backend loaded towards the second half of 2025. Our orderbook and pipeline have matured positively year-to-date, and we are reaffirming the communicated financial guidance for the year," says
Financial highlights as of
- In Q1 2025, revenue amounted to
DKK 3.2 million (DKK 6.2 million for the same period in 2024), primarily driven by revenue fromForward Osmosis Market Development . Based on the observed order traction, revenue will pick up during 2025, with a significant part expected to materialize in the second half of the year. - EBITDA (before special items) was a loss of
DKK 15.3 million in Q1 2025 (a loss ofDKK 19.3 million for the same period in 2024), in line with Management's expectations for the quarter. - As of
March 31, 2025 , cash and cash equivalents wereDKK 58.5 million (compared toDKK 2.0 million as ofMarch 31, 2024 ). - The Company maintains its financial guidance for the full year 2025: Revenue of
DKK 60-80 million ; EBITDA (before special items) a loss ofDKK 45-55 million .
Business highlights Q1 2025
- The Company's strategic accounts focus is materializing through repeat orders from a growing number of customers, decreasing dependence on specific accounts and diversifying our revenue streams.
- Continued collaboration efforts with Gallo, with positive results, achieving excellent concentration quality levels at the pilot scale.
- Signed a strategic framework agreement in
Beijing, China , withLiaocheng Water Group as part of the Sino-Danish Water Alliance China with Grundfos, DIH, and Landson Advanced Ceramics, which is investigating ways to improve industrial wastewater treatment and management inChina .
Subsequent events
- Strengthened presence in South and
Latin America , with orders from system integrator, VOENS, who will utilizeAquaporin's CLEAR Series to improve wastewater recycling processes inChile and to purify well water in Mexico. - Secured pilot plan contract to deliver Forward Osmosis system for
Trinity College Dublin at theIrish Bioeconomy Foundation's National Bioeconomy Campus to develop new processes and products as part of a scale-up research initiative to recover bio-based products. - Sold 500 CLEAR membranes to
Beijing -based company, CZRLO, to help increase energy efficiency significantly at a municipal wastewater incineration plant and a coal chemical plant. - Successfully completed trial with
Singapore's National Water Agency , PUB, which demonstrated good results in line with project expectations - Announced that Chief Executive Officer,
Matt Boczkowski , will step down for personal reasons.Matt Boczkowski will continue in his role until endSeptember 2025 at the latest.
Commentary Q1 2025
In the first few months of the year,
The financial results for the first quarter of 2025 showed a decrease in revenue of
In April, the Company announced that Chief Executive Officer,
For further information, please contact:
+45 53 55 55 19, investorrelations@aquaporin.com
About
Forward-looking statements
Matters discussed in this report may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as "believe", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should", and similar expressions, as well as other statements regarding future events or prospects. Specifically, this report includes information with respect to projections, estimates, and targets that also constitute forward-looking statements. The forward-looking statements in this report are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, and other important factors include, among others: Limited experience in commercialization of the Company's products, failure to successfully implement strategies, dependence on third parties for manufacturing certain product components and the supply of certain raw materials, manufacturing disruptions, strategic collaboration, protection of the Company's intellectual property rights and other risks disclosed in
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Q1 2025 Trading Statement |
|
https://news.cision.com/aquaporin-a-s/i/071119-aquaporin-00867-sh,c3411388 |
071119- |
View original content:https://www.prnewswire.com/news-releases/aquaporin-q1-2025-trading-statement--maintains-full-year-financial-guidance-for-2025-302461543.html
SOURCE